Fluoroquinolones I  by unknown
138 C l i n i c a l  M i c r o b i o l o g y  a n d  I n f e c t i o n ,  Vo lume 5 S u p p l e m e n t  3 
Inhibitory effect of myristic acid analogs on 
picornaviruses 
N. Zare’, H . 2  Grunert’, 0. Raudies’, J. Katzhendler?, A. 
Honigman’, A. Panet’, M. Hodzaev’, A. Kvetnaya’, S .  Swartz*, 
H.  Zeichhardt’ , ‘Department of Virology, Institute for Infectious Diseases 
Medicine, University Hospital Benjamin Franklin, Free Urriversity o f  
Berlin, Germany; ’Faculty $Medicine, 77te Hebrew Urriversity, 
Jerusalem, Israel 
Objectives: Myristoylated proteins are important for picornavirus 
reproduction. Computer modeling of the three-dimensional struc- 
tures ofhuman rhinovirus 14 (HRV14) and poliovirus 1 (PV1) were 
the basis for the design of myristic acid (MA) analogs with modifi- 
cations along the alkyl chain. The MA analogs target the capsid 
protein VP4 to inhibit virus reproduction. 
Methods: The inhibitory effects of the MA analogs on the repro- 
duction of HRV14, PVl and coxsackievirus A21 (CoxA21) were 
tested in HeLa cells. The systems allowed differentiation ofviral repli- 
cation in the first and later reproduction cycles. Virus reproduction 
(0.1-10 m.0.i.) was analyzed for (1) virus adsorption at the host cell, 
(2) viral R N A  synthesis, (3) synthesis of new virus antigen before 
onset of the cytopathic effect (CPE), and (4) virus progeny in MA 
analog-treated and non-treated cells. Virus progeny &om treated cells 
were isolated and characterized in one-step reproduction kinetics. 
Results: The analog MI60 (500 pM) inhibited new virus antigen 
synthesis ofPVl and HRV14 at  the end ofthe first reproduction cycle 
(before CPE onset) by 83% and 90%, respectively. Virus adsorption 
at the host cell and viral RNA synthesis were hardly affected. Virus 
antigen harvested from Ml60-treated cells in later reproduction 
cycles showed strongly reduced infectivity (1.5% compared to non- 
treated virus); however, it was still capable of adsorbing to the host 
cell. 
Conclusions: The M160 analog might target picornavirus matu- 
ration, resulting in structurally altered particles which have lost their 
infectivity but could still recognize the virus receptor on permissive 
cells. 
Fiuoroquinolones I 
Ip2001 In vitro activity of moxifloxacin, a new 
methoxyquinolone, against resistant 
meningococci, Haemophilus influenzae and 
pneumococcal isolates compared to 
therapeutic and prophylactic agents 
EJ.R. Abadi, T.H. Pennington. Department of Medical Mitrobioloxy, 
Aberdeen University Medical School, Aberdeen, UK 
Neisseria meninxitidis, Haemopkilus injrrenzae and Streptococcus pneumo- 
niae are three important meningitis-causing pathogens. Resistance to 
some of the antibiotics u e d  in therapy or prophylaxis poses a serious 
problem, particularly in some countries with a high incidence of 
resistance. Therefore, an antibiotic effective against these bacteria 
would be very valuable for use in empirical therapy and prophylaxis. 
The in v i m  activity of moxifloxacin against nieningococcal 
isolates (n=30), H. injuenzae (n=6) and pneumococci (n=6) was 
determined. The isolates included sensitive as well as resistant strains 
to at least one of the standard therapeutic or prophylactic antibiotics 
used. Moxifloxacin showed very high activity against all the strains. 
MICros for moxifloxacin ranged from 0.008 to 0.05 mg/L for 
Neisseria meninxitidix, from 0.008 to 0.06 mg/L for H. ir$uenzae, and 
from 0.125 mg/L for pneumococci. 
Recent studies have also shown that the antimicrobial is safe and 
tolerable; therefore, it would be a promising agent for empirical ther- 
apy of bacterial meningitis, and clinical trials assessing its efficacy for 
the management of infections caused by these organisms are merited. 
Penetration of moxifloxacin (MFXI into sinus 
tissues following multiple oral dosing 
P. Gehanno’, H. Stass’, P. Arvis’. ’Claude Bernard Hospital, Paris, 
France; ZBnycr AG, Wuppertal, Germany; ’Bqer Pkarma, Puceaux, 
Frarite 
Objectives: To evaluate the penetration and time-course of MFX in 
sinus tissues up to 36 h, after five oral 400-mg doses. 
Methods: A total of 52 patients with chronic sinusitis undergo- 
ing surgery were enrolled in the study from February 1998 to June 
1998. Forty-eight patients (including a control group of 6 patients 
who were not to receive medication) aged 47.1 i: 13.0 years (I 9-69 
years) and weighing 72.1 2 10.8 kg (55-94 kg) were valid for safety 
analysis. A total of 39 patients, including 34 treated patients, were 
valid for PK analysis. MFX was quantified in sinus tissues and in 
plasma obtained from venous blood at corresponding times by a vali- 
dated HPLC method. 
Results: Time after dosing (T), number of patients (n), geom. 
Mean/std. dev concentrations in plasma (P) and niaxillary sinus 
mucosa (MSM), and ratios MSM/P are tabulated below: 
Similar results were observed with anterior ethmoid mucosa and 
nasal polyps. MFX was well tolerated. 
Conclusion: These results indicate that MFX readily and highly 
penetrates into sinus tissues and follows a time-course similar to its 
profile in plasma. In addition, MFX achieves concentrations several- 
fold in excess of the MICcms of all pathogens that cause acute sinusi- 
tis, such as S. pneumoniae (MICW 0.25 mg/L), for at least 36 h 
post-dose at steady state. 
[p2021 The bactericidal activity of moxifloxacin and 
other quinolones against mycobacteria 
S.H. Gillespie, D. Everett. Royal Free and University College Medical 
School, Hamnpstead, London, UK 
Objectives: To develop in vitro methods to determine bactericidal 
activity of moxifloxacin against mycobacteria. 
Methods: M.fortuitnut was used as a model system. Cultures were 
grown in Middlebrook broth and in the presence and absence of 
quinolones at varying concentrations. Viable count was performed at 
3, 6 and 16 h. Using these data it was possible to calculate the opti- 
n d  bactericidal concentration, and bactericidal index. 
Results: Moxifloxacin had a superior OBC (0.5 mg/L) than 
sparfloxacin (1.0 nig/L), ciprofloxacin (2.0 mg/L) and ofloxacin (8.0 
nig/L). 
Conclusion: Moxifloxacin has excellent bactericidal activity 
against M .  fortuitum, and similar studies in slow-growing organisms 
are now underway. 
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I P203 1 Moxifloxacin (MFX) in acute exacerbations of 
chronic bronchitis (AECB)-a bacteriologic and 
clinical meta-analysis 
C. Kraseniann, J.M. Meyer, M. Springsklee. Bayer AG, Pllarma 
Research Center, Wrppertal, Germany 
Objectives: To compare bacteriologic and clinical outcome in four 
inultinational trials in patients with AECB treated with either MFX 
(400 iiig) or comparator (clarithromycin (CLAR)). 
Methods: Pooled patient data on pathogens isolated pre-therapy 
and post-treatment eradication rates were subjected to meta-analysis. 
MICs for the pathogens were determined by Etest. 
Results: Of the efficacy-evaluable population, 47% (477 of 1017) 
were microbiologically valid. Sputum was collected pre-therapy and 
602 pathogens were isolated. The most frequently isolated pathogens 
and the bacteriologic and clinical outcomes for MFX-treated patients 
are tabulated below: 
The mean eradication rate for all isolates conibined (95%) is in accor- 
dance with the high clinical efficacy of MFX (95% resolution/ 
improvement). CLAR was less successful than MFX in eradicating 
H. influenzar (72% versus 97%1 for MFX), consistent with the rela- 
tively high MICs of CLAR for this cpecies. 
Conclusions: MFX was highly successful in ternis of both clini- 
cal efficacy and bacteriologic eradication rates in the treatment of 
AECB. 
(p2041 Moxifloxacin (MFX) in acute sinusitis (AS)-a 
bacteriologic and clinical meta-analysis 
C. Kraseniann, J.M. Meyer, M. Springsklee. Bayer AG, Pliarma 
Research Center, Wiippertal, Germany 
Objectives: To compare bacteriologic and clinical outcome in four 
niultinational trials in patients with AS treated with either MFX (400 
mg) or coinparator (cefuroxime (CFX)). 
Methods: Pooled patient data on pathogens isolated pre-therapy 
and post-treatment eradication rates were subjected to nieta-analyTis. 
MICs for the pathogens were determined by Etest. 
Results: Of the efficacy-evaluable population, 35% (282 of 802) 
were microbiologically valid. Pre-therapy samples were obtained by 
middle meatus swab (31%), sinus cannulation (20%) and sinus punc- 
ture (49%). Bacteriologic and clinical outcome for patients treated 
with MFX (400 nig) are tabulated below: 
i 
The mean eradication rate for all isolates conibined (96%) is in accor- 
dance with the high clinical efficacy of MFX (96% resolution/ 
improvement). The bacteriologic etiology for CFX-treated patients 
was comparable to the MFX-treated population, with slightly lower 
resolution/improvement (90%) and eradication (93%) rates for CFX. 
The modal MFX MIC was 0.25 mg/L for S. pneurwoniae, 0.064 mg/L 
for H .  irlfinenzae and 0.125 mg/L for M .  catarrhalis. 
Conclusions: MFX was highly successful, in terms of both cliii- 
ical efficacy and bacteriologic eradication rates, in the treatment of 
AS. There was slight superiority for MFX over a standard (CFX) 
regimen. 
v1 Moxifloxacin (MFX) in community-acquired 
pneumonia (CAP)-a bacteriologic and clinical 
meta-analysis 
C. Krasemann, J.M. Meyer, M. Springsklee. Baycr AG‘, Plzarnia 
Res~carch Cewter, Wuppertal, Grrniarty 
Objectives: To compare bacteriologic and clinical outcome in  five 
multinational trials in patients with CAP treated with either MFX 
(400 ing) or comparator (amoxycillin (AMOX) or clxithroniycin 
(CLAR)). 
Methods: Pooled patient data on pathogens isolated pre-therapy 
and post-treatment eradication rates were subjected to nieta-analysis. 
MICs for the pathogens were determined by Eteyt. 
Results: O f  the etfcacy-evaluable population, 30% (243 of 799) 
were microbiologically valid. Bacteriologic and clinical outcome for 
MFX-treated patients are as follows: 
Overall bacteriologic success rates were 86% for AMOX and 90% for 
CLAR. In patients treated with MFX. the modal MIC of S. pneu- 
moniae was 0.125 nig/L. irrespective of wsceptibility to penicillin or 
CLAR. MFX was particularly successful against penicillin- and 
macrolide-resistant S. pneunzuniae strains 
Conclusions: MFX was highly successful in terms of both clini- 
cal efficacy and bacteriologic eradication rate5 in the treatment of 
CAP. 
Suggested breakpoints for moxifloxacin (MFX) 
C. Krasemann, J.M. Meyer, M. Springsklee. Bayer AC, Pliarma 
Research Cenfer, Wtippertal, Germany 
Bacterial ‘sensitivity’ and ‘resistance’ to a given antibiotic are defined 
using the following parameters: distribution of MICs in precliiiical 
studies; achievable concentrations in serudtissues; relationship 
between MICs; and eradication in clinical studies. The following 
relationship (all pooled respiratory tract infection (RTI) =skin and 
skin structure infection (SSSI) isolates) was found after treatment with 
MFX (400 mg, ad.): 
Of the causative pathogens, 89-97% were eradicated up to an MIC 
of 2 mg/L; however, only half of the isolates with an MIC of > =4 
mg/L respond to MFX. Consequently, pathogens with an MIC of 
< =2 mg/L should be defined as fully sensitive to MFX. A further 
discrimination between intermediate sensitivity and resistance is not 
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possible in these isolates. The following definitions of critical MIC 
values are suggested: sensitive: MICs <= 2 ing/L; resistant: MICs 
> = 4  mg/L. Based on previous preclinical and clinical results, S. 
pneumoniae, H .  infuenzae, H. parainfuenzae, M.  catarrhalis, K. pneu- 
moniae (and other Enterobacteriaceae) would be included in the cate- 
gory MFX ‘sensitive’, whereas I? aeruginosa, S. maltophilia and B. 
cepacia would predominantly be classed as MFX ‘resistant’. The phar- 
macokinetic data of MFX (e.g. C,,,,,: 2-4 mg/L; epithelial lining 
fluid concentration: -25 mg/L) support this proposal. 
m1 Moxifloxacin (MFX) versus amoxycillin (AMOX) 
in the treatment of community-acquired 
suspected pneumococcal pneumonia: a 
multinational double-blind randomized study 
I? Petipretzl, J. Branco Pines’, J. Dosede13, G. Rico Mendez4, P. 
Arvis5. ‘A. Mignot Hospital, La Chesnay, France; ’Coimbra Hospital, 
Coimbra, Portugal; ’Church Hospital Sisters St Charles Earth, Prague, 
Czech Republic; ‘General Hospital La Raza, Mexico City, Mexico; 
5Bayer Pharma, Pufeaux, France 
Objectives: To compare the efficacy and safety of oral MFX (400 
mg 0.d. for 10 days) with oral AMOX (1 g t i d .  for 10 days) in the 
treatment of adult inpatients or outpatients with community- 
acquired, suspected pneumococcal pneumonia. 
Methods: A total of 41 1 patients with community-acquired, 
suspected pneumococcal pneumonia, that was clinically diagnosed on 
the basis of fever, chest X-ray, respiratory signs or symptoms and in 
addition two or more specific criteria that led to a presumptive diag- 
nosis of pneumococcal pneumonia, were enrolled in the study. 362 
patients (88.1%) were valid for per-protocol (PP) analysis, 177 
(MFX), 185 (AMOX); 136 patients were microbiologically valid, 68 
in each group. 
Results: Clinical success rates in the PP population at end of ther- 
apy (EOT) were: 
MFX 91.5%, AMOX 89.7% (95% confidence interval: -4.2%, 
7.8%). Clinical cure rates at EOT in patients with pen-I or pen-R S. 
pueumoniae pneumonia were MFX 94.4% and AMOX 86.7%. Both 
treatments also effectively maintained their clinical success rates until 
follow-up (21-28 days post-therapy): MFX 89.4%, AMOX 89.3%. 
Bacteriologic success rates at EOT were MFX 89.7% and AMOX 
82.4%. Bacteriologic response analysis by organism confirmed the 
bacteriologic efficacy of MFX against S. prreumoniae: bacteriologic 
success rates were MFX 89.6% and AMOX 84.8%. The incidence of 
drug-related adverse events (AE) was similar in both groups. The 
treatment withdrawal rate due to AE was also similar. 
Conclusions: MFX was at least as effective as AMOX in the treat- 
ment of community-acquired pneumonia including penicillin-insen- 
sitive S. pneumoniae. Analysis confirmed the high clinical and 
bacteriologic efficacy of MFX against S. pneumoniae. 
1-1 Safety and tolerability profile of moxifloxacin 
M. Springsklee, C. Reiter, J.M. Meyer, Bayer AG, Wnppertal, 
Germany 
Objectives: To compare the safety and tolerability profile of moxi- 
floxacin (MFX) to other community respiratory antibiotics. 
Methods: Meta-analysis of the clinical safety database comprising 
a total of 20 phase I1 and 111 trials. 
Results: There were no significant demographic differences 
between groups exposed to MFX (4926 patients with 46641 days 
exposure) and comparators (3415 patients with 33 354 days expo- 
sure). Approximately 90% of MFX patients received 400 nig 0.d. 
Comparators included oral cephalosporins, e.g. cephalexin and 
cefuroxime-axetil, and macrolides, e.g. clarithromycin. Incidences of 
adverse drug reactions (ADR) were low and comparable among all 
treatment groups. The majority ofADR were mild and transient, and 
no unexpected severe reactions occurred. This is reinforced by the 
low overall ADK discontinuation rate observed with MFX (3.8%). 
The most frequently reported ADR with MFX were nausea 
(7.2%) and diarrhea (5.7%). with low discontinuation rates (0.8% and 
0.5%, respectively). Particular attention was paid to know quinolone 
class-effects, e.g. CNS reactions or phototoxicity. Dizziness was 
reported by 2.8% of patients (discontinuation rate 0.5%), indicating 
a low propensity of MFX to cause CNS reactions. There was no 
drug-related case of phototoxicity, which further corroborates that 
MFX is photostable and devoid of photosensitizing potential. 
Conclusions: Analysis of this large clinical database indicates that 
the safety and tolerability profile of MFX compares favorably with 
quinolones recognized to be well tolerated, e.g. ciprofloxacin, as well 
as with current standard community respiratory antibacterials, such 
as cephalosporins and macrolides. MFX represents a safe and well- 
tolerated addition to the community physicians. 
Short-course moxifloxacin (MFX) versus 
clarithromycin (CLAR) in acute exacerbations 
of chronic bronchitis (AECB) 
R. Wilson’, R. Kubin2. ‘Host Defence Unit, National Heart G. Lung 
Institute, London, UK; ’Bayer plc, Pkarmaceutiral Division, Newbury, 
UK 
Objectives: To compare the efficacy and safety of oral MFX (400 
mg, 0.d.) for 5 days with standard treattnent with oral CLAR (500 
ing, b id . )  for 7 days. 
Methods: This was a multinational, randomized, double-blind 
study conducted in 750 patients with AECB characterized by at least 
two of the following symptoms: sputum purulence, increased sputum 
volume and increased dyspnea. 
Results: Seven days post-therapy, clinical cure was achieved in 
89% (287 of 322) of efficacy-evaluable patients in the MFX group 
and 88% (289 of 327) of patients in the CLAR group (95% confi- 
dence interval (CI): -3.9%, 5.8%). At follow-up (21-28 days post- 
treatment), the continued clinical cure rates were 89% (256 of 287) 
for MFX and 89% (257 of 289) for CLAK. A total of 342 patho- 
genic bacteria were isolated from the sputum of 287 patients. The 
most common pathogens were Haemophilus injuenzae (37%), 
Streptococcus pneumoniae (31%) and Moraxella catarrhalis (18%). 
Bacteriologic success rates 7 days post-therapy for MFX were supe- 
rior to CLAR (95% CI: 3.6%, 26.9%), especially the eradication rates 
for the most fiequently isolated pathogen H .  infnenzae. Both treat- 
ments were well tolerated, with comparable incidences for drug- 
related adverse events. 
Conclusions: A 5-day course of MFX (400 mg, 0.d.) is clinically 
equivalent and bacteriologicly superior to a 7-day course of CLAR 
(500 mg, b id . )  in the treatment of patients with AECB. 
[p210] The in vitro activity of moxifloxacin and other 
new quinolones against selected clinical 
isolates 
A. King, J. May, G. French, 1. Phillips. St Thomas Hospital, London, 
UK 
Objectives: To assess the activity of moxifloxacin against clinical 
isolates, including those resistant, or of intermediate susceptibility, to 
ciprofloxacin. 
A b s t r a c t s  1 4 1  
Methods: MICs were determined by an agar dilution method 
with an inoculum of  CFU. The  medium for aerobic organism, 
was Diagnostic Sensitivity Test agar (Oxoid), supplemented with 5% 
lysed horse blood for fastidious organisms (also with 10 nig/L NAD 
for Hacvmphilus ir!%rerirne) and incubated overnight at 37°C in air or 
COz if required for growth. The medium for anaerobic organisms 
was Wilkens Chalgren agar (Oxoid) supplemented with 5% Iysed 
horse blood and incubated for 24-48 h, depending on thc species, at 
37OC in an atmosphere containing 10% hydrogen, 10% carbon diox- 
ide and 80% nitrogen. Breakpoints for nioxifloxacin are sensitive 
<=4 mg/L, resistant =8 mg/L 
Results: Moxifloxacin, like trovafloxacin, grepafloxacin and 
clinafloxacin, was much more active than ciprofloxacin against all 
Gram-positive aerobes. and many isolates resistant to ciprofloxacin 
were sensitive to moxifloxacin. Moxifloxacin was equal to or  slightly 
less active than ciprofloxacin against most Gram-negative aerobes, 
except Arirtefobarter spp. and S. rnultop,philia, and Gran-negative isolates 
resistant to ciprofloxacin were also resistant to inoxifloxacin. Moxi- 
floxacin, like trovafloxacin and cliiiafloxacin, was much more active 
than ciprofloxacin against all anaerobic bacteria tested. 
Conclusions: Moxifloxacin is similar in activity to trovafloxacin 
and grepafloxacin and is more active than ciprofloxacin against Gram- 
positive and anaerobic bacteria. 
m1 Prophylaxis of staphylococcal foreign body 
infection: enhanced activity of moxifloxacin 
versus ciprofloxacin in a rat model 
E. Van WiJngaerden, W.E. Peetermans, J. Van Eldere. Iilfections 
Diseases Research Groirp, Uriiwrsity I$ Lruveii, Lmverr, Belqiurn 
Objectives: To determine the relative efficacy of moxifloxacin and 
ciprofloxacin in a rat rmidel of prophylaxis of foreign body infection. 
Methods: One-cni polyurethane catheter segments were iiicu- 
bated for 2 h at O°C in a siispension of S. epidermidis strain 11 1 (MIC 
ciprofloxacin 1 mg/L, moxifloxacin. 0.25 nig/L) to carry an iiiocu- 
luin of 104 CFU/catheter. Catheters (n=21 in each group) were 
implanted subcutaneously in inbred Fisher rats. Prophylaxis was 
administered by oral gavage 3 h before, at the time of and 3 h after 
implantation in 10 mg/kg quinolone doses or placebo. Catheters 
were explanted after 72 h, sonicated and cultured quantitatively. 
Results: The  mean (SD) logli, CFU/catheter recovered was 6.1 
(0.5) in the placebo group, 6.1 (0.4) in the ciprofloxacin group and 
4.7 (1.3) in the moxifloxacin group (j<O.O001 for the comparison 
with placebo and ciprofloxacin). 
Conclusions: In this rat model of foreign body infection a signif- 
icant prophylactic effect could be demonstrated with the new 
quinoloiie moxifloxacin compared to ciprofloxacin and placebo. The 
use of inoxifloxacin ac part of a prophylactic strategy at implantation 
of medical devices warrants further investigation. 
m1 Lack of interaction between moxifloxacin and 
combined oral contraceptive steroids 
K. Sachse, H. Stass, H .  Delesen, H. Adelmann, R. Heinig, R 
Horstniann, K. Ochniann, M. Ziihlsdorf. Instifiitr of Clinirai 
Pliarnidrology, Baycr AG, Wnpperta/ /Colopie ,  Grrniany 
Objectives: Several antibiotics have been reported to influence the 
ovarian suppression produced by oral hormonal contraceptive agents. 
In this study, a possible failure of contraception in women taking the 
8-methoxyquinolone moxifloxacin, a new broad-spectrum antibi- 
otic, was investigated. 
Methods: In a randomized, double blind, pldccbo-controlled, 
two-way crossover study 29 healthy young females ,raying on long- 
term therapy with a combined oral contraceptive (cthinylestradiol 
0.03 mg  and levonorgestrel 0.15 mg) were adinini\tered 400 mg 
moxifloxacin 0.d. on cycle days 1-7. There was a wa\hout pha\e of 
at least one menstrual cycle between the two periods. lllood wiiples 
were taken on days 19-21 for measurement of progesteronc. on days 
5-8 and 19-21 for estradiol, and on days 5-8 for LH and FSH. In 
addition, the pharniacokinetic profiles of moxifloxacin, ethmylestrci- 
dial and levonorgestrel were determined on day 7. 
Results: Progesterone was suppressed in all woiiieii well below 2.0 
ng/niL on all measurements, indicating absence of ovulation. Also. 
estradiol, LH and FSH were suppressed througlioiit the study, with 
no difference in the two different periods. In .idditiori, pharmacoki- 
netic profiles of ethmylestradiol and levonorgectrel were alniojt iden- 
tical with and without concomitant inoxifloxacin treatment. 
Conclusions: There are no  hints for .i drug intcr~ction between 
nioxifloxacin and combined oral hormonal contraccption. 
Prospective, double-blind, randomized, 
comparative study on the influence of 
multiple-dose moxifloxacin (MOX) versus 
clarithromycin (CLA) on normal fecal flora in 
volunteers 
G. Beyer', M.  Hiemer-Bau', S. Ziege', M.  Rau ' ,  G. Schrciber', 
C.E. Nord', H.  Lodc'. 'Deparf tnenf  .f Cliest atid I$ertions Disrases. 
City Hospital Z e / d e m h j ;  @. Freir Urriiasrtdr Berlirr, Berlirr, 
Gerrnarry; 'Department c!f Irnrnurrolyq, Mirrohiolqy, Patlioli>~qy and 
Irlfecrious Diseases, Hnddiqc, Uiiivercify Hosyital, Hiiddirge, S L I P ~ F P ~  
Objectives: Evalu'ition of a multiple-dow treatment ~ i t l i  MClX on 
intestinal flora in comparison to a treatment with C L A  2nd the rcsult- 
ing development of resistant microorganisms ni normal volunteer\. 
Methods: This single-center, multiple-dose, randomized, double- 
blind, controlled, crossover trial was performed in 12 healthy, young, 
male Caucasian siibjrcts between 18 and 40 (inclusive) year$ of age. 
Fecal samplec were taken before, during and after a 7-day treatment 
with MOX (400 mg per oe, once daily) o r  CLA (500 tng per o s ,  
twice a day). Qualitative and quantitative fecal culture\ were 
performed by standard methods. 
Results: No severe adverse events were observed during both 
treatnients. Fecal flora during the treatment with MOX: transient 
decrease of Gifenirorcus 'pp., E. coii, bifidobacterid and clostridia and 
a limited increax of Cuirdida spp. Fecal flora during the tre~itmeiit 
with CLA: significant long-term decrease of bitidobxteria; transient 
decrease of lactobacilli, clostridla and E. coli, and a limited incr 
of Caridida spp. 
Conclusions: In comparison with clarithromycin, MOX treat- 
ment resulted in a sipificant decrease of enterococcl, an only trail- 
sient decrease of bifidobacteria and no significant impact on 
lactobacilli. 
)p2141 In vitro activity of moxifloxacin (MOX) and 
other fluoroquinolones (FQ) against 
Streptococcus pneumoniae (Pnc) isolates for 
acute otitis media (AOM) 
N. I'eled, P. Yagupsky, 0. Katz, R. Dagaii. Bctr-Giuro/i I irirwsity of 
t h e  Nqct ' ,  Bcrr-Skeufl, Isrucl 
Background: MOX IS a novel FQ with documented dctlvlty against 
Gram-positive organisms, including antibiotic-resimnt Pnc, and thus 
IS of potential benefit for the treatment of Pnc AOM. 
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Methods: MOX in vitro activity against middle ear fluid (MEF) 
Pnc isolates was compared to that of ciprofloxacin (CI), spadoxacin 
(SO), levofloxacin (LE), trovafloxacin (TV) and grepafloxacin (GP), 
by using Etest. 56 Pnc isolates obtained from MEF of children with 
AOM from southern Israel were tested. 
Results: 43 (77%) isolates were penicillin non-susceptible, of 
which 9 were fully resistant. Co-trimoxazole, erythromycin, clin- 
damycin and tetracycline resistance was present in 32 (57%), 15 
(27%), 8 (14%), and 12 (21%), respectively, while 11 (20%) were 
susceptible to all drugs. 37 (66%) and 13 (23%) isolates were resistant 
to two drugs and three drugs, respectively. MICsos to CI, SO, LE, 
TV, GP and MOX (mg/mL) were 1.0, 0.25, 0.75, 0.94, 0.25 and 
0.19, respectively. The respective MICuos were 3.0, 0.5, 1.0, 0.125, 
0.50, and 0.25. When an arbitrary MIC value of 0.5 mg/L was 
chosen, 93% and 82% of isolates were above this value for CI and 
LEV respectively, versus <=2 of the other FQs. An elevated MIC 
value of any given quinolone was associated with increased MlCs of 
all others. MICs of quinolones did not correlate with resistance to 
penicillin, cotrimoxazole, erythromycin, clindamycin or tetracycline. 
Conclusions: MOX has a potential role in AOM caused by 
antibiotic-resistant Pnc and compares favorably against other new 
FQs. 
MFX 1 MFX+srrum TFX 1 lTX+wtum 
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[p215( The in vitro activity of moxifloxacin (BAY 12- 
8039) in comparison to other newer 
fluoroquinolones against enteropathogenic 
bacteria 
S. Schubert, U. Ullmann, R. Krausse. Medical Microbiology, 
University uJKid, Kid, Germany 
Objectives: The susceptibility of enteropathogenic bacteria as 
Salmonella spp. (n= 100). pathogenic E. coli spp. (EHEC n= 10, EPEC 
n=10), Campylobacterjejuni/coli (n= 10) and Helimbacterpylori (n=  10) 
to moxifloxacin (Bay 12-8039) (MFX), ciprofloxacin (ClP), trova- 
floxacin (TFX), levofloxacin (LFX), grepafloxacin (GPX) and gati- 
floxacin (GTX) was determined (concentration range 0.015-32 
Methods: The investigated strains were non-copy isolates from 
feces of symptomatic patients. The MIC values for Salmonella spp. 
and E. coli were evaluated by the microdilution test according to DIN 
(German Institution for Standardization) guidelines, which require 
Mueller-Hinton broth and an inoculum size of 5 X 10s CFU/mL. 
The MIC testing of Campylobacter spp. and H. pylori was done by agar 
dilution. 
PdmL). 
Results: MICW values (mg/L): 
Conclusions: The activity of levofloxacin against Canipylobacter 
jejuni/coli was rather poor. With regard to H. pylori, ciprofloxacin was 
the only considerable agent. Against Salmonelia spp., EHEC and 
EPEC, however, the fluoroquinolones tested, including moxi- 
floxacin, had M I G O  values which were well attainable at a therapeu- 
tic dosage. 
Ip216] In vitro activity of moxifloxacin, four other 
quinolones and three non-quinolone antibiotics 
against obligately anaerobic bacteria 
G. Ackermann, R. Schaumann, B. Pless, M. Clams, A.C. Rodloff. 
Institute of Medical Microbiology, University ofkipzk, hip,+, 
Germany 
Objectives: The new quinolone moxifloxacin waq tested for its in 
vitro activity against 292 clinical isolates of obligately anaerobic 
bacteria employing the broth microdilution technique. 
Methods: We assessed the antimicrobial activity of moxifloxacin 
and other selected antibiotics (trovafloxacin, gatifloxacin, levo- 
floxacin, ciprofloxacin, meropenem, metronidazole and clindamycin) 
against the following 292 strains: Bacteroides fvagilis (Bfra, n=62), 
other Bacteroides spp. (Bact, n= 135), Prevotella spp. (Prev, n= 11). 
Fnsobacteritim spp. (Fuso, n=17), Bilophila wadsworthia (Bilo, n=29), 
Clostridinm spp. (Clos, n=29), and Peptostreptococcus spp. (Pept, n=9). 
MICs were determined eniploying the broth microdilution tech- 
nique and Wilkens-Chalgren broth. 
Results: M I C S I ~ M I C W  values were as follows: 
Conclusion: These results indicate that moxifloxacin is slightly 
less active than trovafloxacin, as active as gatifloxacin. and more active 
than levofloxacin and ciprofloxacin. Thus moxifloxacin may have a 
therapeutic role in anaerobic infections. 
Moxifloxacin and trovafloxacin: effect of 
human serum on bactericidal activity against 
Kiebsiella pneurnoniae and Streptococcus 
pneumoniae 
U. Ullmann, S. Schubert, A. Dalhoff. Medical Microbiology, 
University of Kiel, Kid, Germany 
Objectives: The effect of human serum on the antibacterial effect 
of moxifloxacin (MFX) and trovafloxacin (TFX) was measured. 
Methods: (1 )  Three serum-resistant Klebsiella pnetimoniae strains 
were cultivated in a nutrient broth containing 70% normal human 
serum and a constant concentration of 0.125 mg/L MFX or 0.06 
mg/L TFX (i.e. IXMIC). (2) Furthermore, the fluctuating serum 
concentrations following P.O. dose of 400 mg MFX and 200 mg TFX 
were simulated in an in vitro model; one strain each of K. pnenmo- 
niae and S. pneumoniae were used in the kinetic model. The colony- 
forming units (CFUs) were determined with the poured plate 
technique immediately after inoculation (lo6 CFU/mL) and after 
incubation for 1, 2, 3, 4, 5, 6 and 24 h at 37'C. Serum-free cultures 
served as controls. 
Results: (1) Time-kill results (CFU/mL) with constant quinolone 
concentrations: 
6 1  32x10' I 21x102 I 52x10' I 53x10' 
24 I 84x10' I 58x106 I 83x10' I 37x10' 
A b s t r a c t s  
___ ~~~ 
Antimicrobial 
1 4 3  
Pen-S (MIC 60.06 mgW 
MIC, I MIC, I MIC,, 
1 Pen-I (MIC 0 Conclusions: ( 1 )  While human serum decreased the activity of 
TFX against K. pncumoniae, the activity of MFX was clearly 
increased. (2) The simulation of human serum kinetics in serum free 
medium resulted iii an elimination of both species within 12 h by 
MFX and TFX; addition of 70% serum did not affect the activity of 
MFX, whereas the activity of TFX was reduced by 99%. 
I P218 I In vitro activity of trovafloxacin, moxifloxacin, 
grepafloxacin, ofloxacin, ciprofloxacin and 
sparfloxacin against Streptococcus 
pneumoniae isolated from bacteremic 
pneumonia 
R.R. Reinert, K. Lutticken. National Reference Centerfor 
Streptococci, Utriucrsiry Horpiral Aachen, Germany 
Objectives: Trovafloxacin is a new fluoroquinolone with enhanced 
activity against Gram-positive bacteria. In this study the in vitro activ- 
ity of this compound against S. pneumoniae was determined in 
comparison with other quinolones. 
Methods: One hundred and seventy-four penicillin-susceptible 
strains of S. pneunioniae isolated from blood cultures of pneumonia 
patients, and 26 penicillin-intermediate isolates from different 
sources, were collected between 1992 and 1996 in Germany MIC 
values for trovafloxacin, moxifloxacin, grepafloxacin, ofloxacin, 
ciprofloxacin, sparfloxacin, erythromycin, penicillin and tetracycline 
were determined by the agar dilution method. 
Results: Quinolone activity was unaffected by penicillin or 
erythromycin resistance, with MICjo/MICcw (nig/L) of: 0.125/0.25 
(trovafloxacin and rnoxifloxacin); 0.25/0.5 (grepafloxacin); I .O- 
2.0/4.0 (ofloxacin and ciprofloxacin); 0.25/0.5 (sparfloxacin). 
Erythromycin and tetracycline were less active against penicillin- 
intermediate strains (erythroniycin, MIC<m= 8 mg/L; tetracycline, 
M I C ~ I I  64 mg/L) compared to penicillin-susceptible strains 
(erythromycin, M I C ~ I I  0.5 mg/L; tetracycline, MICw=8 nig/L). 
Conclusions: Trovafloxacin showed the highest activity of d l  
quinolones investigated. This compound is a promising agent for the 
treatment of pneuniococcal respiratory tract infections, including 
those caused by penicillin- or macrolide-resistant strains. 
Im] In vitro activity of SB-265805 against 
Streptococcus pneumoniae in Germany 
R.K. Reinert', A. Al-Lahham', R. Liitticken', K. Machka'. 
'Nafiunal Refrefice Cmter.for Streptococci, Uniuevrity Hospital Aaclien, 
'SmirhKline Beechant Plramia, Munich, Germany 
Objectives: This study evaluated the in vitro activity of the new 
fluoronaphtyridone SB-265805 against S. pneumoniae in comparison 
with nine other agents. 
Methods: 200 S. pneunioniae isolates were tested; 174 were 
isolated from blood cultures and 26 penicillin-intermediate (Pen-I) 
isolates were also included. MICs were determined by the microdi- 
lution inethod using Mueller-Hinton broth plus 5% lysed horse 
blood, according to the NCCLS guidelines. S. pneumoniae ATCC 
49619 was included for quality control. Antibiotics tested included: 
S13-265805, moxifloxacin, grepafloxacin, spartloxacin, levofloxacin, 
ciprofloxacin, ofloxacin, erythromycin, tetracycline and penicillin G. 
Results: Results are shown below: 
Moxifloxacin 
Grepafloxacin 
Sparfloxacin 
Levofloxacln 
Clprofloxacin 
Ofloxacin 
Erythromycin 
Tetracycline 
0.125 0.25 0.125 
0.25 I 0.5 I 0.25 
I .o 
2.0 
0.125 0.25 
0.25 
2-1 mg/L) 
MIC, 
0.06 
0.25 
0.5 
0.5 
2.0 
4.0 
4.0 
8.0 
264.0 
Conclusions: SB-265805 demonstrated the highest in vitro activ- 
ity of all fluoroquinolones tested. SB-265805 is a very promising 
agent for the treatment of pneuniococcal infections. 
w1 Moxifloxacin: tentative interpretative criteria 
for disk susceptibility testing using the 
German DIN 58940 method 
H. Grinim. Laboratory Dr Giirfner, Wein'prten, Germany 
Objectives: To calculate interpretative criteria for inhibition zones 
obtained with 5-mg moxifloxacin disks. 
Methods: 314 non-fastidious pathogens, partially with reduced 
susceptibility to ciprofloxacin, 101 H .  injiumzae, 25 M. ratavrhaiis and 
41 S. pneirmoniae were studied using Mueller-Hinton agar and 
Haernophilus Test Medium, respectively MIC determinations for 
moxifloxacin were done by Etest and zone diameters were measured 
using 5-mg disks and a semiconfluent inoculum, according to DIN 
58940. The correlation between MICs and inhihition zones war 
calculated by the method of least squares. 
Results: No resistant strains were observed within the group of 
fastidious pathogens. Therefore the regression line war calculated for 
the non fastidious species only. The strains of H .  infiuenzm and M. 
catarrliolii fit into the scattergram of the non-fastidious speciep. In 
contrast to these RTI pathogens, S. pneunioniae regularly exhibits rela- 
tively smaller inhibition zones, despite MICs of only 0.03-0.5 mg/L. 
Breakpoints for moxifloxacin are not defined so far. When applying 
the breakpoints of < = 1 rng/L for susceptibility and =4 mg/L for 
resistance (recommended by DIN 58940, e.g. for ciprofloxacin and 
ofloxacin), the following inhibition zones would correspond: 
resistant intermediate susceptible regresslon formula r 
</=18mm 19-21mm >/=22mm x=-0 348 y+17 086 -0.928 
If the DIN-recommended breakpoints depart from those valuer 
assumed here, corresponding zone sizer must be recalculated. 
Conclusions: Interpretative criteria for inhibition zones of nioxi- 
floxacin can be defined together for non-fastidious organism\, 
Haeniophilns and Moraxella. For S. pneuinoniae, however, a scparate 
evaluation is necessary. 
(p2211 SB-265805 (LB 20304a): activity compared to 11 
drugs against Haemophilus influenzae and 
Moraxella catarrhalis 
L. Kelly, D. Hoellnian, S .  Bajaksouzian, A. Zillet, M. Jacobs, P 
Appelbaum. Herskry Medical Centcr, Hershey, PA; Clasc " e s t e n r  
Reserve University, Cleveland, O H ,  U S A  
Objectives: To test activity of 53-265805, a broad-spectrum 
quinolone, against 171 H .  it$uenzae and 50 M .  tanwrhalis compared 
to ciprofloxacin, levofloxacin, spatfloxacin, grepafloxacin. trova- 
floxacin, ampicillin, amoxycillin ?clavulmate, crfixinie, cefuroxime 
and azithroniycin. 
Methods: Microdilution MIC according to NCCLS was used. 
Results: MICjll/.j~,s (nig/L) were as follows: 
1 4 4  C l i n i c a l  M i c r o b i o l o g y  a n d  I n f e c t i o n ,  Volume 5 S u p p l e m e n t  3 
H.inR LLac + (103)H.lnfi &-Lac - (68) M.catarrhalis (50) D w  
88-265805 0.008/0.015 0.008/0.015 0.016/0.016 
Ciprofloxacin 0.015/0.015 0.01510.015 0.03/0.03 
Levofloxacin 0.03/0.03 0.03/0.03 0.06/0.06 
Sparfloxacin 0.015/0.03 
Grepafloxacin 0.008/0.008 
TrovaRoxacin 0.01 5/0.03 
Ampicillin >16.0/>16.0 
Amoxicillin > 16.0/>16.0 
Amox/elav 1.012.0 
Cefixime 0.0310.03 
Cefumxime 0.511 .O 
Azithmmycin 2.0/4.0 
0.015/0.03 
0.00810.01 5 
0.015/0.03 
0.25/0.25 
0.5/0.5 
0.510.5 
0.0310.03 
0.511.0 
2.014.0 
0.03/0.03 
0.008/0.016 
0.03/0.03 
4.0/8.0 
4.018.0 
0.12510.25 
0.2510.25 
2.012.0 
0.0610.06 
Conclusions: AmoxyciUin/clavulanate MICs were < ~ 4 . 0  
mg/L, cefixime 1 4 . 1 2 5  mg/L, cefuroxime <=8.0 mg/L and 
azithromycin < ~ 4 . 0  mg/L. Grepafloxacin and SB- 265805 had the 
lowest MICs of all agents tested. 
(p2221 In vitro activity of SB-265805 versus 
gatifloxacin, moxifloxacin, trovafloxacin, 
ciprofloxacin and ofloxacin against 
uropathogens 
K.G. Naber, K. Hollauer, D. Kirchbauer, W. Witte. Urologic Clinic, 
Hospifal St Elisabeth Straubinf, Robert Koch Institute, Wernigerode, 
Germany 
Objectives: To determine the minimum inhibitory concentrations 
(MICs) of SB-265805 verw gatifloxacin, moxifloxacin, 
trovafloxacin, ciprofloxacin and ofloxacin against uropathogens. 
Methods: 367 uropathogens were cultured from the urine of 
urologic patients with complicated and/or hospital-acquired urinary 
tract infections (UTI). The bacterial spectrum consisted of 
Enterobacteriaceae (1 12), enterococci (125), S. aureus (27), coagu- 
lase-negative staphylococci (56), and non-fermenting bacteria (47). 
MICs were determined using an agar dilution method. 
Results: SB-265805 inhibited all strains of Enterobacteriaceae up 
to an MIC of 1.0 mg/L (MIC9o 0.25 mg/L). For the total bacterial 
spectrum, SB-265805 inhibited 80.7% 85.3%. 90.5% and 95.4% of 
strains up to an MIC of 0.5 mg/L, 1 mg/L, 2 mg/L, and 4 mg/L, 
respectively. If an MIC breakpoint of < = 1 mg/L is used for suscep- 
tible strains, the following rates of susceptibility were found, in order 
of decreasing susceptibility rate: SB-265805 85.3% trovafloxacin 
84.5%, moxifloxacin 82.0%, gatifloxacin 80.9%, ciprofloxacin 60.5% 
and ofloxacin 52.9%. If an MIC breakpoint of / = 4  mg/L is used for 
resistant strains, the following rates of resistance were found, in order 
of increasing resistance rate: SB-265805 9.5%, moxifloxacin 13.1%, 
gatifloxacin 13.6% trovafloxacin 13.9%, ciprofloxacin 18.0% and 
ofloxacin 42.2%. 
Conclusions: According to its in vitro activity, SB-265805 can 
be considered a promising alternative fluoroquinolone agent for the 
treatment of complicated UTI. 
1-1 Bactericidal activity of 88-265805 in 
experimental Streptococcus pneumonias 
meningitis 
A. Smirnov, A. WeUmer, S. Henne, H. Schmidt, R. Nau. 
Department of Neurology, University .f Goftingen, Germany 
Objectives: To study the activity of SB-265805 against S. pneumo- 
niae in an in vivo model of S. pneumoniae meningitis. 
Methods: NZW rabbits were infected intracisternally with 10' 
CFU of a penicillin-sensitive S. pneumoniae type 3 strain (MIC for 
SB-265805 <=0.03 mg/L). Between 12 and 24 h after infection, 
they were treated with the mesylate salt (75.4% pfb) of SB-265805, 
5 mg/kg per hour (n=9), 1 mg/kg per hour (n=8) or 5 mg/kg per 
hour=dexamethasone 1 mg/kg (n=9), or ceftriaxone 10 mg/kg per 
hour (n=12). To reach steady state rapidly, treatment was initiated 
with a bolus equaling 2 hourly doses. CSF was sampled at 12, 14, 17, 
20 and 24 h to determine bacterial count, lactate and protein concen- 
trations and leukocyte densities. Bactericidal activity in CSF was esti- 
mated by log-linear regression of bacterial titers over time. 
Concentrations of SB-265805 in CSF and serum were determined 
by agar diffusion. 
Results: 5 mg/kg per hour of SB-265805 mesylate salt reduced 
bacterial counts in CSF almost as rapidly as ceftriaxone 10 mg/kg per 
hour (delta log CFU/niI per hourCSD: -0.2510.09 versus 
-0.3820.1 1, respectively). The concentration of SB-265805 in 
serum and CSF was 3.022.0 mg/L and 0.27'0.07 mg/L at 14 h, 
and 2.1211.37 mg/L and 0.59-C-0.38 mg/L at 24 h, respectively. 
Administration of dexamethasone 1 mg/kg 15 min prior to 5 mg/kg 
per hour SB-265805 had no effect on SB-265805 activity (delta log 
CFU/mL per hour2SD: -0.26C0.11) or serum or CSF levels 
(2.69k1.33 mg/L, 0.29k0.19 mg/L at 14 h and 2.6951.39 mg/L, 
0.75C0.34 mg/L at 24 h, respectively). However, there was a non- 
significant reduction in CSF protein and lactate concentrations. At a 
dose of 1 mg/kg per hour, SB-265805 was less effective (delta log 
CFU/mL per hourfSD: -0. 15f0.19), with respective serum and 
CSF concentrations of0.7020.41 mg/L and 0. 1720.13 mg/L at 14 
h and 0.57C0.40 mg/L and 0.17k0.09 mg/L at 24 h. 
Conclusion: The in vivo activity suggests that SB-265805 may 
prove useful for the treatment of S. pneumoniae meningitis. 
(p224( Antipneumococcal activity of SB 265805 (LB 
20304a) (a new broad-spectrum quinolone) 
compared to nine compounds 
G.A. Pankuch, L.M. Kelly, M.R. Jacobs, P.C. Appefbaum. Hershey 
Medical Center, Herskey, PA; Case Western Reserve University, 
Cleveland, OH, USA 
Objectives: To test antipneumococcal activity of SB 265805. 
Methods: Standard agar dilution tested activity of SB 265805, 
ciprofloxacin, levofloxacin, sparfloxacin, grepafloxacin, trovafloxacin, 
amoxycillin, cefuroxime, azithromycin and clarithromycin against 55 
penicillin-susceptible, 46 penicillin-intermediate and 43 penicillin- 
resistant pneumococci (12 with ciprofloxacin MICs 8 mg/L). 
Results: MICsd~os (mg/L) were as follows: 
D W  
Penicillin G 0.016/0.06 0.2511.0 4.0/4.0 
SB 265805 0.0310.06 0.016/0.06 0.03/0.06 
Ciprofloxacin 1.Ol4.0 1.012.0 2.014.0 
Levofloxacin 1.0/2.0 1.0/2.0 1.0/2.0 
Sparfloxacin 0.25/1.0 0.25/0.5 0.5/0.5 
Grepafloxacin 0.1 2510.25 0.125/0.25 0.125/0.25 
Trovafloxacin 0.125/0.125 0.125/0.25 0.125/0.25 
Amoxicillin 0.016/0.06 0.12511.0 2.012.0 
Cefuroxlme 0.0310.25 0.512.0 8.0116.0 
Azilhrornycin 0.12510.5 0.1251>64.0 4.0b64.0 
Cfarithromycin 0.03/0.06 0.03/>64.0 2.0P64.0 
Pen S Quin S Pen I Quin S Pen R Quin S Quin R 
0.016/2.0 
0.125/0.25 
16.01232.0 
16.0/532.0 
8.0l232.0 
8.018.0 
2.0/8.0 
0.016/1.0 
0.0 16/4.0 
0.06/>64.0 
0.03b64.0 
Conclusions: SB 265805 had the lowest MICs (0.004-0.5 mg/L, 
overall M I C ~ ~ M I C Y I I  0.03/0.125 mg/L), including against 
ciprofloxacin-resistant strains, followed by trovafloxacin and 
grepafloxacin, sparfloxacin, levofloxacin and ciprofloxacin. B-Lactam 
and macrolide MICs rose with those of penicillin. 
A b s t r a c t s  145 
Grepafloxacin: comparison of different 
methods for MIC determination of 
Streptococcus pneumoniae 
R.R. Reinert', K .  Huber', R. Lutticken'. 'National Referenre 
Center& Stnptococti, Universiry Hospital Anckcln, 'Glnxo Wellcomc, 
Hanthq,  Gcrmaiiy 
Objectives: Grepafloxacin is a new fluoroquinoloiie with enhanced 
activity against S .  pnennmoiiiae. Results of recent in vitro studies have 
varied when using different methods for MIC determination. This 
study evaluated the influence of different methods (microbroth dilu- 
tion, agar dilution, Etest) on results of MIC determination. 
Methods: MIC values (grepafloxacin, ofloxacin, ciprofloxacin, 
sparfloxacin, erythromycin, penicillin, and tetracycline) of 174 clin- 
ical isolates of S. pneniiiouiae isolated from normally sterile body sites 
and 26 penicillin-intermediate isolates from other sources were deter- 
mined by the agar dilution method, the microbroth method and the 
Etest. 
Results: Quinolone activity (agar dilution method) was unaf- 
fected by penicillin or erythromycin resistance with MICSI~/MIC~II  
(iiig/L) of 0.25/0.5 (grepafloxacin) 1 .O-2.0/4.0 (ofloxacin and 
ciprofloxacin), and 0.25/0.5 (sparfioxacin). Erythromycin and tetra- 
cycline were less active against penicillin-intermediate (erythro- 
mycin, MlCo0=8 nig/L; tetracycline, MICs[l=64 mg/L) compared 
to penicillin-susceptible strains (erythromycin, MICso=0.5 mg/L; 
tetracycline, MICsll=8 mg/L). Grepafloxacin MICs (geometric 
mean MIC, 0.30 mg/L) determined by the microdilution method 
(NCCLS) were slighly higher compared to agar dilution results 
(geometric mean MIC, 0.23 mg/L). MICs determined by Etest were 
nearly identical to agar dilution results. 
Conclusions: Results of our  study indicate excellent antipneu- 
mococcal activity of grepafloxacin. MIC values may differ in indi- 
vidual prieumococcal strains when using different methods for MIC 
determination. This compound is a promising agent for treatment of 
pneuniococcal respiratory tract infections, including those with peni- 
cillin- or niacrolide-resistant strains. 
Ip226] In vitro susceptibility of Borrelia spp. to 
grepafloxacin 
P. Anda, R. Escudero, J. Rodriguez-Villanueva, K. Sellek, C N M -  
frisritnto de Salrtd, Carlos lfl, Bacteriolqx Madrid ,  Spain 
Objectives: To determine the in vitro activity of grepafloxacin 
(GlaxoWellconie) against Bur& spp. compared to that of doxicyclin 
and ceftriaxone (Sigma), the two drugs of choice used against human 
borrelioses (Lynie disease (LD) and relapsing fever (RF)). 
Methods: MICsil and MICVI, were determined for 20 strains of 
the B .  brr~do@vi sensu lato and RF-causing borrelia groups by the 
broth macrodilution method. MICs were determined as the lowest 
concentration of antimicrobials preventing growth (lack of color 
change compared to antimicrobial-free growth control and absence 
of spirochetes as seen by dark field microscopy). 
Results: Grepafloxacin inhibited the growth of 19/20 borrelias 
(MICjl,=0.5; MICWI= 1 ing/L). Doxicyclin showed similar results 
(MICil, and MICpl,=0.5 mg/L) and ceftriaxone lower values (0.015 
and 0.06 mg/L), according to previous descriptions. B. liermsii was 
most resistant to grepafloxacin (MIC=2 mg/L) and sensitive to 
ceftriaxone (MIC=0.06 ing/L). The other RF-causing borrelia, B. 
pavkcri, was the most sensitive m a i n  to grepafloxacin (MIC <0.0625 
mg/L), being the most resistmt to ceftriaxoiie (MIC 0.24 ing/inL). 
Both presented equal MICs for doxicyclin (0.5 mg/L). 
Conclusions: Grepafloxacin has good in vitro activity against 
Borrclia, similar to doxicyclin. MICil, values were much lower than 
F 
the levels of grepafloxacin described in human serum and intracellu- 
lar compartments. The cause of the level of resistance of B .  ltrrimii 
to grepafloxacin will be evaluated. 
lp2271 in vitro activity of grepafloxacin against clinical 
isolates obtained from laboratories in the 
European Union 
S.E Kinghorn-Perry', M. Pontre', J. Jupp', A. Moult2, ILN. 
Gruneberg'. 'GR Micro Limited, London, 'Clam Wrllcoine plr, 
Middlesex, UK 
The in vitro activity of grepafloxacin, a potent broad-spectrum fluo- 
roquinolone, was determined against 5000 isolate\ of \eveii different 
species of bacteria. MICs were determined following N<:<:LS guidc- 
lines. Isolates were obtained from 29 tenters located throughout the 
European Union. For isolates of Str~ptomrcur piieirmoriinc, Hnmopliiliis 
inflnenzae and Moraxella catarrlnalis there was little varimon iii the 
modal MIC,,II for grepafloxacin. MIC distribution data for S. piicw 
inoriiae showed very similar patterns in all countritx I n  inost coun- 
tries, 100% of strains were susceptible. Grepafloxacin-resistant 
pneumococci were found only in France (n=3),  Germany ( n = l ) ,  
and Spain (n=2). The MICW for strains received from 27 centers (12 
countries) was 0.25 iiig/L; from the remaining two centers, value5 of 
0.12 mg/L and 0.5 mg/L were obtained. In all countries, lOO'% of 
Haemophiliis influenax, H.  paratn~uerizne and .44 catarrlralis strains 
were susceptible to grepafloxacin. MICw and MICPII values did not 
vary significantly between countries; H .  rnfltrenzac sti-am? from 22 
centers had an MICW of0.015 nig/L, four centers 0.0081 mg/L and 
two centers 0.031 mg/L. A total of 1389 strain5 of Stuphylomccirs 
acirws were coiiected. For inethicillin-susceptible isolatcs (pi= 11 h4) 
the overall susceptibility was 98.2% with an MICo,, of 0.121 mg/L, 
increasing to 161 ing/L if inethicillin-resistant strains were included. 
For E. d i  and K. pnertnioninc respectively, the overall susceptibility to 
grepafloxacin was 92.4% and 96.1'%. The results obtained from this 
study show that grepafloxacin IS highly active, with good consistrncy 
of data being obtained for organisms isolated in different countries 
[p2281 Efficacy and tolerability of grepafloxacin: 
results of a German surveillance study in 9398 
patients 
W. Elm'  , E Vogel', H. Lode'. 'Staedtisclre Kliriikerz, Bidcfcld, 
'h.lain-Tarriins-l(linikcn, Hc$wirn, 'Lui ip ik l in ik  Heckeslrorri, Berlipi, 
Germany 
Objectives: To investigate the efficacy and tolerability of 
grepafloxacin in a large number of outpatients, including those with 
underlying diseases and concomitant medications. 
Methods: In a retrospective, open, multicenter surveillance study 
in Germany, efficacy and tolerability of grepafloxacin administered 
under everyday general practice conditions were investigated in 9398 
patients with community-acquired respiratory tract infections (KTI). 
Results: Main indications were acute exacerbation of chronic 
bronchitis (AECB: n=5540) or community-acquired pneumonia 
(CAP: n=2213) followed by acute severe bronchitis (n=479), sinusi- 
tis (n=197) and sinubronchitis (ii=164j. Over 70% of the patients 
received 400 mg grepafloxacin once daily; 600 nig once daily was 
used primarily for patients with CAP. Overal clinical response was 
rated as very good or good in 96.7%, moderate in 2.1'%1 and poor in 
0.6%. Only 2.3% of patients reported adverse events. The most 
frequently reported events were nausea (0.8%) and gastrointestinal 
symptoms (0.4%). Dizziness was only reported in 0.3% and only four 
patients (0.04%) reported photosensitization. In patients receiving 
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one or more concomitant medications ( n  =7310), tolerability was 
assessed separately (96.7% very good or good, 1.8% moderate, 0.5% 
poor) and comparable to the total population and to the subgroup of 
patients (n=3135) receiving concurrent theophylline. 
Conclusions: These data emphasize that grepafloxacin is a highly 
effective, well-tolerated fluoroquinolone suitable for the treatment of 
community-acquired RTI. 
Patients treated Ratio of successfully 
successfullv within heated DatieIItS. __ - 
GFX-5 
GFX-10 
CLA-lo@ 
per Course the fixed budget rela'uve to CLA 
91% 5750 167 194 
"'95% 10514 95 111 
86% 10521 86 1 00 
Statistically significant in comparison with CLA-10 ($0.01). *+ 
@ Retail price of one supplier for a course of 20x250 mg. 
Conclusions: In comparison with CLA-10, 94% more patients 
can be successfully treated with GFX-5, and 11% more patients can 
be successfully treated with GFX-10, within a fixed drug budget in 
Germany. 
w1 In vitro activity of grepafloxacin against human 
isolates of Brucella melitensis 
A. Garcia-Pascual, B. Hernbndez-Novoa, A. Duenas, M. Ortega, J. 
Rodriguez-Villanueva, I .  Montes-Martinez, R. Abad, M.A. Bratos, 
A. Orduna, A. Rodriguez Torres. Hospital Clinico Valladolid; 
Hospital Comarcal Plasencia, Ciiieres; Medical Department, 
Glaxo Wellcome, Spain 
Objectives: To evaluate the susceptibility to grepafloxacin of human 
isolates of Brrrcella melitensis. 
Methods: The minimal inhibitory concentrations (MICs) of 
grepafloxacin were determined in solid medium for 151 human clin- 
ical isolates of Bnrcella melitensis according to NCCLS recomnienda- 
tions. Grepafloxacin minimal bactericidal concentration (MBC) and 
time-killing curves for 10 isolates were evaluated following the tech- 
niques of the ASM Clinical Microbiology Procedures Handbook. 
Results: Grepafloxacin MICso was 0.5 mg/L, and MICr,] was 1.0 
mg/L (range: 0.062-2 mg/L). Grepafloxacin MBC values for the 10 
tested isolates ranged from 0.25 mg/L to 2 mg/L. Bactericidal activ- 
ity of grepafloxacin was observed after 24 h at MICw equivalent 
concentrations. After 48 h, bacterial killing of grepafloxacin was 
complete at 4-fold MICqo. 
Conclusions: Grepafloxacin exhibits good bactericidal activity 
against human clinical isolates of Enriella melitemis. 
Table (mg/L): 
Strain no: 14, 63, 134, 164, 170, 171, 172, 173, 174, 175 
MBC: 2, 0.25, 0.5, 0.5, 0.25, 0.25, 1, 1, 1, 1 
MICw: 0.5, 0.25, 0.25, 0.125, 0.25, 0.125, 0.5, 0.5, 0.5, 0.5 
lntraphagocytic activity of grepafloxacin 
against intracellular Brucella melitensis 
A. Garcia-Pascual, A. Prado, l? Alonso, P. Gutierrez, M.A. Miguel, 
J. Rodriguez-Villanueva, M.A. Bratos, A. Orduiia, A. Rodriguez 
Torres. Hospital Clinico Valladolid; Hospital Comarcal Monfirte de 
Lemos Lngo; Medical Department, Glaxo Wellcome, Spain 
Objectives: To assess the bactericidal activity of grepafloxacin against 
Brucella melitensis phagocytosed by human polymorphonuclear leuko- 
cytes (PMN). 
Methods: Human polymorphonuclear leukocytes were obtained 
from 7 healthy blood donors and isolated by differential centrifuga- 
tion. Brtrcella melitensis 16M was opsonized with anti-Brucella human 
IgG. Brucella cells (20 000 000 CFU/mL) were incubated with PMN 
(10 000 000 cells/mL) for 30 min at 37°C. Extracellular remaining 
bacteria were eliminated by streptomycin treatment and differential 
centrifugation. Intracellular bactericidal activity of grepafloxacin was 
evaluated by adding the antibiotic to the tubes containing the 
cell suspension a t  2 X MBC (minimal bactericidal concentration), 
1 XMBC, 0.5XMBC, and 0.25XMBC (0.5-0.0625 mg/L.). 
Number of the surviving CFU/mL was determined after 30 and 60 
iiiin of incubation at 37°C and continuous shaking. 
Results: Grepafloxacin exhibits intraphagocytic bactericidal activ- 
ity at all the concentrations tested. No significant differences were 
observed between 30- and 60-min experimental time points. 
Ecological effect of gatifloxacin on the normal 
human intestinal microflora 
C. Edlund, C.E. Nord, Karolinsk Institute, Immunohfl, Mimbioloa, 
Stockholm, Sweden 
Objectives: To study the impact on the normal intestinal microflora 
of orally administered gatifloxacin, a new broad-spectrum fluoro- 
quinolone. 
Methods: Gatifloxacin was given in oral doses of 400 mg once 
daily for 10 days to 18 healthy volunteers. Fecal samples were 
collected prior to administration (day -4 and day -I), during the 
administration period (days 5 and 10) and after withdrawal of admin- 
istration (days 12, 16, 22, 30 and 50). The samples were diluted in 
pre-reduced media and inoculated aerobically and anaerobically on 
selective agar media. The composition of the intestinal flora was 
analyzed qualitatively and quantitatively. 
Results: In the aerobic intestinal microflora, Escherichia coli strains 
were eliminated or strongly suppressed during the administration 
period and the numbers of enterococci decreased significantly, while 
the numbers of staphylococci increased at the same time. In the 
anaerobic microflora the numbers of clostridia and fusobacteria 
decreased significantly during the administration period, while no 
other major changes occurred. The microflora was normalized 40 
days after the administration of gatifloxacin had stopped. No selec- 
tion or overgrowth of resistant bacterial strains or yeasts occurred. 
A b s t r a c t s  1 4 7  
Conclusions: The ecological impact of gatifloxacin was shown to 
be selective and similar to that of quinolones like ciprofloxacin, 
levofloxacin and ofloxacin. 
128 ing/L, range: 4-1 28 mg/L). MIC:c for newer fluoroqultlolones 
were only moderately lower than MICs for CFX. The lowest MIC511s 
were shown by GFX (MlCsI,= 1 mg/L) and CNFX and Pl)-l17596 
(MICj!l= 0.5 mg/L). CNFX showed, oveall, the best activity 
(range = 0.06-8 nig/L). 
I P233 1 Drug interaction of gatifloxacin (GTX) with an 
aluminum-magnesium-containing antacid 
S. Labor', S. Ziege', M. Rau', G. Schreiber', L? Koeppe', H. 
Lode'. 'Departnieiit cf' Chat and Ittfictions Dimses, City Hospital 
Heckeskorn, 'Department 4 Physics and Laser Medicine, Kliriikum 
Betljamiri Frnnklin, Frcjie Uniuersrtat Berlin, Germariy 
Objectives: Concomitant administration of the new fluoro- 
quinolone GTX with an aluminuni-magnesium-containing antacid 
(maloox) might lead to a reduction of the absorption in the upper 
gastrointestinal tract, through formation of a insoluble chelate 
complex. 
Methods: We assessed the pharmacocinetics (Pk) and interaction 
of GTX and iiiaalox at different time points. In each part ofthe study 
12 healthy volunteers received either GTX alone (A and D), or 
concomitantly with inaalox (C), or maalox 2 h before (B), 2 h after 
(E), or 4 h after GTX dosing (F). GTX concentrations were 
measured by validated bioassay and HPLC methods. 
Results: The Pk data ofa single oral dose of GTX alone (400 mg) 
were as follows (mean2SD): C,,,,, 3.820.5 mg/mL at 1.420.8 h 
(T,,,,l,, A); C,,,,, 3.150.9 mg/L at 1.720.7 h (T,,,,,, D); t i m  8.651.4 
h (A)/7.551.2 h (D); AUC ~ . ~ , , f i , , , ~ ~  33.525.9 mg h/mL 
(A)/31.4?3.4 mg h/mL (D); total urine recovery (URmt ) 8356%) 
(A)/8428% (D). Maalox intake 2 h before (B) or concomitantly with 
GTX (C) decreased theAUC,~.r,,fi,,,~~ highly significantly by 42% or 
even 64%. When inaalox was given 2 h after GTX (E), the AUCrl. 
~ , , f i , , ~ ~ ~  was significantly reduced by 18% (P<O.Ol). Maalox adminis- 
tratioii 4 h after GTX (F) showed no influence on the GTX 
absorption. 
magnesium-containing agents should be spaced by 4 h. 
Conclusions: The adininistration of GTX and aluminum- 
In vitro activity of eight fluoroquinolones 
against R-lactam-resistant Stenotrophomonas 
maltophilia clinical strains 
S.J. Sinchez Hernindez, M.N. GutiCrrez Zufiaurre, M.A. Alonso 
Maiizanares, S. Mu~ioz Criado, J.L. Murioz Bellido, J.A. Garcia- 
Rodriguez, Hospital Clirriro, Dept. de Microbiologia, Salamanca, Spain 
S. maltopliilia is a noii-fermentative Gram-negative bacterium caus- 
ing growing concern, because of it$ increasing incidence in critical 
arras and frequent niultiresistance. Older fluoroquinolones can be 
occasionally useful against these inici-oorganisms, though resistance is 
frequent. Newer fluoroquinolones are now becoming available that 
might have increased effectiveness against S. maltophilia. We have 
tested the activity of eight fluoroquinolones against B-lactam-resis- 
tant S. mairophilia clinical strains. We selected 49 S. maltophilia clini- 
cal strains resistant, a t  least, to piperadin and ticarcillin, and tested 
them against ceftazidiine (CAZ), norfloxacin (NFX), ciprofloxacin 
(CFX), grepafloxacin (GFX), trovafloxacin (TFX), gatifloxacin 
(GTFX), clinafloxacin (CNFX), PD-117596 and PD-138312 by the 
agar dilution method. As there are no NCCLS defined standards for 
S. nraltopkilia, we used those defined for l? aeruginosa. More than 50% 
of strains were also resistant to CAZ (MICSo= 64 mg/L, MlCw= 
128 mg/L, range: 1-128 mg/L). All the 49 strains were also resistant 
to CFX (MICSII= 2 mg/L, M I C ~ I I =  16 mg/L, range: 1-128 nig/L). 
MICs against NFX were even higher (MICjn= 32 mg/L, M I C ~ I I =  
ml In vitro activity of gatifloxacin (A-1155) against 
grfA single mutant Sraphyfococcus aureus 
clinical strains 
M.A. Alonso Manzanares', M.C.M. Toldos', M.N. Guti6rrcz 
Zufiaurre', G. Yagiie Guirao', A. Palop', J.L. Murioz Bellido', M. 
Segovia', J.A. Garcia-Rodriguez' . 'Departnient of Microl~iolo~qy, 
Hospital Universitario de Salamanca, Salamanca, 'DqJartuierit qf 
Microbiulogx Hospital Gerieral thiversitario, Mitrcia, 'Service qf 
Microbiolofx Hospital Rio Hortqa, I/alludolid, Spain 
Objectives: Gatifloxacin (A-1 155) is a new h-fluoro-X-methoxy- 
quinolone that has been shown to be effective against both (;rani- 
positive and Gram-negative bacteria. One of the advantages of other 
newer tluoroquinolones is their high degree of effectiveiies\ against 
Grain-positive xrlA mutant strains, similar to the effectivencss against 
wild-type strains, that makes difficult the selcction of- pL4/<qyrA 
double mutant strains. We studied the activity of gatifloxacin against 
wild-type and grlA mutant S. aureus clinical strain\. 
Methods: We selected 39 S. aurrus clinical strain5 wild-type for 
XyrA, gyrB andgrlA, and five grlA mutant strains (three Ser 80 to I'he 
and two Glu 84 to Lys). We studied the in vitro activity of 
ciprofloxacin, ofloxacin, trovafloxacin, grepafloxacin, moxifloxacin 
and gatifloxacin (A-1 155) by the agar dilution niethod, according to 
NCCLS standards. 
Results: The MICq,, of ciprofloxacin against wild-type strain\ was 
0.2 nig/L. MICs against@A mutants were 10 times higher (2 mg/L). 
The behavior of ofloxacin and levofloxacin was similar (MICW for 
wild type=0.14.2 mg/L, MICs0 for BrlA mutants=O.S-l nig/L). 
Newer fluoroquinolones were more active against wild-type strain\, 
(MICo11=0.01-0.06 mg/L) and BrlA mutations led to no increase or 
a very low increase of MICs (no more than four times) 
Activity of ciprofloxacin and other quinolones 
against clinical isolates of Proteus mirabilis 
J.R. Hernindez, L. Martinez-Martinez, A. Pascual, A.I. Suirer, 
E.J. Perea. Department oj-Microbiolon, University Hospital V Mnrarem, 
and School o f  Medicine, Sevillr, Spain 
Objectives: To evaluate both trends in wsceptibility to CIP and in  
vitro activity of seven quinolones against clinical isolates of Proteirs 
mirabilis (Pni). 
Methods: ldentification and susceptibility testing of Pm from 
clinical samples was performed with commercial systems (Pasco 
(April 1990 to March 1996) and Microscan WalkAway (April 1996 
to October 1998)). MICs (mg/L) of nalidixic acid (NAL), pipeinidic 
acid (PIP), norfloxacin (NOR), CIP, pefloxacin (PEF), trovafloxacin 
(TRO) and clinafloxacin (CLI) were determined by inicrodilution 
against 74 isolates selected on the basis of their preliminary suscepti- 
bility to quinolones as determined by WalkAway panels. 
Results: The percentages of susceptibility to CIP (MIC <= 1 
mg/L) among clinical isolates of Pm were: 99.3 (1990&92), 93.7 
(1993-94), 91.2 (1995-96), and 83.8 (1997-98). After the MICs of 
NAL against the 74 selected Pni were determined, organisms were 
divided into NAL susceptible (S; MIC: <= 16 (n=15)) and NAL 
resistant (R; MIC: > = 32 ( ~ = 5 9 ) ) .  MICiirs and MIC'IIIS were: 
148  Clinical  M ic rob io logy  and In fect ion,  Vo lume 5 Supp lement  3 
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I NAL I PIP I NOR 1 CIP I PEF I TRO I CLI 
S MIC, 8 2 0.03 0.015 0.125 0.25 0.015 
MIC. 16 4 0.125 0.015 0.25 0.25 0.015 
Conclusions: CIP susceptibility of Pm has continuously 
decreased during this decade. Cross-resistance to quinolones in CIP- 
resistant Pm was noted. Against Pm, CLI was the most active of the 
quinolones tested. 
Tolerability/toxicity 
Ip2371 Ciprofloxacin inhibits experimental fracture 
healing 
P.M. Huddleston, M.S. Rouse, K.E. Piper, A.D. Hanssen, R. Patel, 
J.M. Steckelberg. Mayo Clinic, Rochester, MN, U S A  
Previous studies of quinolones have demonstrated chondrotoxicity to 
developing articular cartilage in juvenile mammals. Fracture repair 
involves cartilage formation followed by differentiation into cancel- 
lous bone, an analogous situation to developing articular cartilage. We 
compared the healing of experimental fractures in rats after 
ciprofloxacin exposure versus no ciprofloxacin exposure. 40 male 
Wistar rats were divided equally to receive either ciprofloxacin (50 
mg/kg) b.i.d. or no treatment for 21 days beginning 7 days after 
production of experimental bilateral non-displaced implant-stabilized 
femur fractures. Four weeks post-fracture, the animals were sacrificed 
and femurs harvested for mechanical strength testing, and radiologi- 
caand histologic examination. 
N 30min Toque Torsional Rigidity 
Ser Conc Mean Nmm fS.E. Mean Nmm / deg S E .  
NoTreatment 20 -- 338 f 17 39 fo.9 
Cipmfloxacin 20 5.4 284 f8 20 f 1.1 
Torque and torsional rigidity testing results were analyzed by rank 
sum analysis. Radiographic analysis revealed a decreased amount of 
bridging callus and delayed healing in the ciprofloxacin-exposed 
group. Microscopically, the ciprofloxacin-exposed fractures 
contained decreased cartilage cellularity, fibrous proliferation, and 
matrix degeneration. Ultrastructural changes included decreased 
collagen production, and cell membrane disruption. The torsional 
rigidity of experimental fracture callus was significantly (p<0.05) less 
after ciprofloxacin exposure early in the fracture repair process than 
after no treatment. 
lp2381 A new method for testing the chondrotoxicity 
of ciprofloxacin 
G. Seiberl, M. Egerbacher, I. Waiter, B. Wolfesberger. Departmertt 
o j  Infectious Diseases, KFJ-Hospital, If’ienna Institute ~$Histologx 
University oj I gterinary Medicine, I’ienna, Austria 
Objectives: Ciprofloxacin, a frequently used fluoroquinolone, is 
wpposed to be chondrotoxic in juvenile humans, since animal stud- 
ies have shown damage of articular cartilage in weight-bearing joints. 
Mg-free diet leads to similar lesions. It is speculated that quinolone- 
induced arthropathy is due to chelation of magnesium. This divalent 
cation is important for regular function of integrins, a group of trans- 
membrane proteins which connect extracellular matrix proteins with 
the cytoskeleton. 
Methods: We cultivated rat and human chondrocytes in CFX- 
supplemented and Mg-free medium in order to test in vivo findings 
and to elucidate the possible role of integrins in this drug’s side effects. 
In addition, we performed attachment assays to test the ability of 
chondrocytes to adhere to collagen type I1 in the presence of 
ciprofloxacin and in an Mg-free environment. 
Results: Chondrocytes cultivated in CFX-supplemented medium 
(160 I/mL) or Mg-free medium showed decreased ability to adhere 
to growth support, cell shape changes, alterations in actin and 
vimentin cytoskeleton, and reduced proliferation rate (3% compared 
to 81% in control culture). Attachment of chondrocytes to collagen 
type 11-coated cover slips was reduced by 20% in the CFX group 
and 55% in the Mg-free group on day 1. This effect even increased 
after 4 days of culture in the respective medium (by 80% in the CFX 
and Mg-Gee group). 
Conclusions: Mg deficiency might exert its action via integrins, 
resulting in decreased ability to attach to extracellular matrix proteins 
and cytoskeletal changes. This is a possible explanation of cartilage 
lesions found in vivo. Our attachment assay proves to be an easy-to- 
use experimental set-up to test ciprofloxacin and other quinolones 
for their chondrotoxic effects. 
Effects of ciprofloxacin on cartilage in juvenile 
beagles 
R. Stahfmann, S. Kiihner, M. Shakibaei, R. Schwabe, D. Van 
Sickle. Freie Uniuersitiit Berlin, Institutfiir Toxikologie, Berlin, Germany 
We studied the effects of ciprofloxacin in immature Beagles. 1C-11- 
week-old dogs were dosed orally for 5 days with 0 (n=3), 30 ( n = 5 ) ,  
or 200 ( n = 5 )  mg ciprofloxacin/kg body weight. Plasma concentra- 
tions were measured by HPLC 1 h after dosing. In view of the high 
doses used, the plasma concentrations were rather low. For example, 
peak concentrations in the high-dose group were 6.6k0.9 mg/L (day 
l ) ,  3.9k1.4 mg/L (day 3) ,  and 2.6k1.6 mg/L (day 5). In control 
dogs and in dogs treated with the low dose of ciprofloxacin, no 
pathologic changes were seen by light microscopy. However, cleft 
formation and erosions were observed in joint cartilage from 2 of 5 
dogs treated with 200 mg/kg. Using antibodies against a B1-integrin, 
fibronectin and collagen type 11, the effects were studied by immuno- 
histochemistry. The most sensitive alteration was an increase in 
fibronectin, which was detectable in the vicinity of the lesions in 
cartilage samples from the high-dose group dogs. Electron 
microscopy revealed alterations in chondrocytes from dogs treated 
with ciprofloxacin, e.g. swollen mitochondria and enlarged endo- 
plasmic reticulum. 
Data are part of the doctoral thesis of Susanne Kiihner to be 
submitted to the Fachbereich Humanmedizin, Freie Universitat 
Berlin. 
Supported by a grant from BAYER AG, Wuppertal, Germany. 
P240 I Quinolone-induced chondrotoxicity in 
immature rats can be reduced by magnesium 
and tocopherol 
R. Stahlmann, E. Lozo, K. Pfister, R. Schwabe, M. Shakibaei, J. 
Vormann. Freie Universitd Berlin, Institurfur Toxikologie, Berlin, 
Germany 
Quinolones induce joint cartilage lesions in immature animals; iden- 
tical joint cartilage lesions can be induced by feeding a magnesium- 
deficient diet. We now tried to find out whether cartilage lesions can 
be diminished if quinolone-treated immature rats (31 days old) are 
supplemented with additional magnesium. To avoid pharmacokinetic 
